These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 27394428)

  • 81. Efficacy of denosumab therapy after alendronate treatment for a 66-year-old woman with Camurati-Engelmann disease and osteoporosis: a case report.
    Uehara M; Nakamura Y; Suzuki T; Takahashi J; Kato H
    Mod Rheumatol Case Rep; 2020 Jan; 4(1):131-134. PubMed ID: 33086975
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
    Doria C; Mosele GR; Solla F; Maestretti G; Balsano M; Scarpa RM
    Minerva Urol Nefrol; 2017 Jun; 69(3):271-277. PubMed ID: 27813398
    [TBL] [Abstract][Full Text] [Related]  

  • 83. How Long to Treat with Denosumab.
    Costa AG; Bilezikian JP
    Curr Osteoporos Rep; 2015 Dec; 13(6):415-20. PubMed ID: 26474564
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Denosumab-related hypocalcaemia in chronic kidney disease.
    Yong CH
    Aust J Gen Pract; 2018 Aug; 47(8):538-539. PubMed ID: 30114884
    [No Abstract]   [Full Text] [Related]  

  • 85. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
    Cowan A; Jeyakumar N; McArthur E; Fleet JL; Kanagalingam T; Karp I; Khan T; Muanda FT; Nash DM; Silver SA; Thain J; Weir MA; Garg AX; Clemens KK
    J Bone Miner Res; 2023 May; 38(5):650-658. PubMed ID: 36970786
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis.
    Fontalis A; Kenanidis E; Prousali E; Potoupnis M; Tsiridis E
    Expert Opin Drug Saf; 2018 Apr; 17(4):413-428. PubMed ID: 29350565
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study.
    Nakamura K; Kaya M; Yanagisawa Y; Yamamoto K; Takayashiki N; Ukita H; Nagura M; Sugiue K; Kitajima M; Hirano K; Ishida H; Onoda C; Kobayashi Y; Nakatani E; Odagiri K; Suzuki T
    BMC Cancer; 2024 Feb; 24(1):218. PubMed ID: 38360579
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.
    Spångeus A; Rydetun J; Woisetschläger M
    Osteoporos Int; 2024 Jan; 35(1):173-180. PubMed ID: 37750930
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A Simple-to-Use Score for Identifying Individuals at High Risk of Denosumab-Associated Hypocalcemia in Postmenopausal Osteoporosis: A Real-World Cohort Study.
    Kim KJ; Hong N; Lee S; Kim M; Rhee Y
    Calcif Tissue Int; 2020 Dec; 107(6):567-575. PubMed ID: 32920682
    [TBL] [Abstract][Full Text] [Related]  

  • 91. In brief: Severe hypocalcemia with denosumab (Prolia) in chronic kidney disease.
    Med Lett Drugs Ther; 2024 Mar; 66(1697):40. PubMed ID: 38412278
    [No Abstract]   [Full Text] [Related]  

  • 92. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of denosumab treatment in chronic liver disease patients with osteoporosis.
    Saeki C; Saito M; Oikawa T; Nakano M; Torisu Y; Saruta M; Tsubota A
    World J Gastroenterol; 2020 Sep; 26(33):4960-4971. PubMed ID: 32952342
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805705
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
    Park SY; Kim J; Chung HY
    Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 97. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
    McCormick BB; Davis J; Burns KD
    Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects and management of denosumab discontinuation.
    Chapurlat R
    Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
    [No Abstract]   [Full Text] [Related]  

  • 99. Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.
    Cheng BC; Chen YC
    Clin Rheumatol; 2017 Apr; 36(4):929-932. PubMed ID: 27757701
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
    Blackley S; Anderson K; Berg J
    J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.